Compare Neurocrine Biosciences Inc (NBIX) vs SP Funds S&P 500 Sharia Industry Exclusions ETF (SPUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs SP Funds S&P 500 Sharia Industry Exclusions ETF — how do they compare? Neurocrine Biosciences Inc trades at $156.1 (market cap $15.77B), while SP Funds S&P 500 Sharia Industry Exclusions ETF trades at $58.5. The key difference: SP Funds S&P 500 Sharia Industry Exclusions ETF is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| NBIX | SPUS | |
|---|---|---|
Market Cap | $15.77B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $185.50 | $59.51 |
52-Week Low | $123.10 | $46.65 |
Enterprise Value | $15.78B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% on the day, with a bearish technical signal from moving averages. The stock shows strong fundamentals, including a 20.91% net income margin and robust revenue growth, with Q1 2026 EPS beating expectations. Recent news highlights institutional buying and pipeline progress, but safety concerns for Vykat XR have caused volatility.
The outlook is positive given analyst consensus of $207.07 price target and 86% buy ratings, supported by Ingrezza's growth and new drug launches. Key risks include drug safety issues, competitive pressures, and execution challenges in expanding the portfolio, which could impact shareholder returns amid current bearish technical trends.
SPUS trades at $58.72, down 0.53% on the day, with technical indicators showing a neutral to bullish bias. The stock exhibits stable support near $58-59, while moving averages suggest underlying strength. Recent corporate actions include small dividend payments, though key financial ratios are unavailable in the provided data. No significant news has impacted the stock recently, leaving price action driven by broader market sentiment.
The outlook remains neutral with technical support providing a floor, but fundamental clarity is lacking due to missing financial data. Risks include potential volatility from unreported earnings and competitive pressures. Analyst sentiment appears mixed, requiring updated financial disclosures for a clearer investment thesis.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About SP Funds S&P 500 Sharia Industry Exclusions ETF
SPUS tracks a market-cap weighted index of S&P 500 stocks that adhere to Sharia law. It screens out companies involved in non-compliant business activities such as alcohol, tobacco, gambling, and conventional finance, as well as excluding sectors like Aerospace & Defense, and Data Processing. By focusing on low-leverage stocks, SPUS provides investors with a value-conscious, ethically-aligned exposure to a diversified portfolio of large-cap U.S. equities.
Read more on SPUS →
